Stockreport

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALSStandard ALS Measure ALSFRS-R already demons [Read more]